Analyst firms · Morgan Stanley · MDT

Morgan Stanley MDT price target and rating history

Medtronic plc. (MDT) · Health Care

Morgan Stanley rates Medtronic plc. (MDT) Overweight with a $104 price target, as of its latest action on May 30, 2023. It has published 4 rating actions on MDT since August 2021, including 1 upgrade and 1 downgrade. Across 8 firms with a MDT price target in the last 12 months, the median target is $107.

Current rating
Overweight
Price target
$104
Median target, all firms
$107
Actions on MDT
4

Morgan Stanley price target on MDT

$154$129$10420222023202420252026
Morgan Stanley price target on MDT, each point a stated target, August 2021 to May 2023.

Every Morgan Stanley rating on MDT

How other firms rate MDT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Piper SandlerOverweight$120Nov 17, 2026
BarclaysEqual Weight$95Oct 7, 2026
NeedhamBuy$114Aug 27, 2026
UBSBuy$100Jul 28, 2026
BTIGBuy$90Jun 4, 2026
Goldman SachsNeutral$84May 21, 2026
CitigroupBuy$117Feb 3, 2026
Wells FargoOverweight$114Jan 30, 2026
William BlairOutperformJan 6, 2026

Questions about Morgan Stanley and MDT

What is Morgan Stanley's price target for MDT?
Morgan Stanley's latest stated price target for Medtronic plc. (MDT) is $104, from its action on May 30, 2023.
What is Morgan Stanley's rating on MDT?
Morgan Stanley rates MDT Overweight, a bullish rating, as of May 30, 2023.
When did Morgan Stanley last change its view on MDT?
On May 30, 2023, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $104.
How does Morgan Stanley's MDT target compare with other analysts?
Across 8 firms with a MDT price target in the last 12 months, the median target is $107.

More MDT rating histories

All Morgan Stanley ratingsMDT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.